Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Fruquintinib provides improvement in overall survival for refractory mCRC

Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA

$Fruquintinib provides improvement in overall survival for refractory mCRC ( Dr Nageshwara Arvind Dasari - MD Anderson Cancer Center, Houston, USA )$

ESMO 2022: Breast cancer highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ESMO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non...

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation ( Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA )

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Emerging systemic therapies in rare urothelial cancer variants

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

Emerging systemic therapies in rare urothelial cancer variants ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA

Lenvatinib plus pembro for aRCC - update on the CLEAR study ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast...

Prof Matthew P Goetz - Mayo Clinic, Rochester, USA

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple...

Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands

Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer ( Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands )

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum...

Prof Siow-Ming Lee - University College London, London, UK

Atezolizumab improves on single-agent chemo for NSCLC not eligible for platinum-containing regimen ( Prof Siow-Ming Lee - University College London, London, UK )

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in...

Prof Siow-Ming Lee - University College London, London, UK

Results from a phase 3 study of 1L atezolizumab vs single-agent chemotherapy in pts with NSCLC ( Prof Siow-Ming Lee - University College London, London, UK )

RADICALS-HD trial: androgen deprivation therapy with post-operative...

Prof Chris Parker - Institute of Cancer Research, Sutton, UK

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer ( Prof Chris Parker - Institute of Cancer Research, Sutton, UK )

More from ecancer